Telmisartan + Metoprolol Succinate
Information about Telmisartan + Metoprolol Succinate
Telmisartan + Metoprolol Succinate Uses
Telmisartan+Metoprolol Succinate is used in the treatment of Hypertension (high blood pressure).
How Telmisartan + Metoprolol Succinate works
Telmisartan + Metoprolol Succinate is a combination of two blood-pressure lowering medicines: Telmisartan and Metoprolol Succinate. Telmisartan is an angiotensin receptor blocker (ARB). It works by blocking the chemical angiotensin, thereby relaxing blood vessels. Metoprolol Succinate is a beta blocker which works specifically on the heart to reduce heart rate and lower blood pressure. Together they allow the blood to flow more smoothly and the heart to pump more efficiently.
Common side effects of Telmisartan + Metoprolol Succinate
Headache, Weakness, Dizziness, Cold extremities, Slow heart rate, Increased potassium level in blood, Numbness of extremity, Decreased blood pressure
Available Medicine for Telmisartan + Metoprolol Succinate
MetosartanSun Pharmaceutical Industries Ltd
₹163 to ₹1962 variant(s)
Tazloc-BetaUSV Ltd
₹154 to ₹2092 variant(s)
Telsar BetaTorrent Pharmaceuticals Ltd
₹172 to ₹2142 variant(s)
TelmaxxGlenmark Pharmaceuticals Ltd
₹64 to ₹2263 variant(s)
Telmikind BetaMankind Pharma Ltd
₹107 to ₹1372 variant(s)
Telvas BetaAristo Pharmaceuticals Pvt Ltd
₹90 to ₹1152 variant(s)
Metpure-TelEmcure Pharmaceuticals Ltd
₹127 to ₹1752 variant(s)
Arbitel-MTMicro Labs Ltd
₹100 to ₹1393 variant(s)
Met XL-TAjanta Pharma Ltd
₹198 to ₹3134 variant(s)
Telmed BetaMedley Pharmaceuticals
₹141 to ₹2082 variant(s)
Expert advice for Telmisartan + Metoprolol Succinate
- You have been prescribed Telmisartan + Metoprolol Succinate for the treatment of high blood pressure.
- Lowering blood pressure reduces chance of future heart attack & strokes.
- It may cause dizziness. Get up slowly when rising from a sitting or lying position.
- Do not stop taking the medication suddenly without talking to your doctor as it can cause sudden increase in your blood pressure.